| 主权项 |
1. A method of prevention, treatment or lessening of the severity of a condition or disease associated with or characterized by increased, excessive or inappropriate fibrosis comprising administering to a subject in need thereof a compound of Formula (I) or a pharmaceutical composition thereof: or an E or Z isomer thereof, syn or anti isomer thereof, an optically pure isomer thereof, or pharmaceutically acceptable salt thereof, wherein: A is absent or optionally substituted mono or bicyclic heterocycle; B is optionally substituted aryl or heteroaryl; X and Y are independently NR6 or CO; or X and Y taken together form an optionally substituted five membered monocyclic heteroaryl ring, comprising 1 to 4 heteroatoms independently selected from the group of N, O and S, and the remaining non-hetero atoms are carbon; Z is absent or C═O, C═S, C═NOR7, NR8R9, NR10COR11, NR12COOR13 and OR14; R1 is optionally substituted aryl or heteroaryl; R2 is alkyl, alkoxy, thioalkyl, alkoxyalkyl or alkylthioalkyl; R3 and R4 are independently H, C1-6alkyl, alkoxyalkyl, alkylthioalkyl, aryl, benzyl CONR8R9, or COOR13; R5 is absent, mono or bicyclic heteroaryl; R6, R7, R8, R9, R10, R11, R12, R13, and R14 are independently selected from H, C1-6alkyl, alkoxy, optionally substituted aryl or heteroaryl; R15 is one or more H, CONR18R19, OR20, optionally substituted aryl, heteroaryl, benzyl, alkyl, cycloalkyl or heterocycloalkyl; R18, R19, R20 are independently H or alkyl, or R18 and R19 taken together with the nitrogen attached to them to form a heterocycloalkyl group; and n=1 to 4 |
